Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

Do you plan to undergo radiation therapy for a cancer in the abdomen or pelvic region? You may be able to take part in a research study to help us learn if a fatty acid supplement can improve quality of life by limiting GI upset during radiation therapy.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.

Have you been diagnosed with Advanced Renal Cell Carcinoma? If so, you may be able to take part in a research study investigating the optimal way to combine or sequence therapies in patients with renal cell cancer with bone metastasis.

There is very little knowledge about why Chinese-speaking Asians develop eating disorders. In this study, we want to understand the symptoms and genetic risks of eating disorders among Chinese-speaking Asians.

Do you have locally advanced, inoperable, node-positive non-small cell lung cancer (NSCLC), stage II or III? If so, you may be able to take part in a study to learn more about the effectiveness of adding stereotactic body radiation therapy (SBRT) to the standard treatment of radiation and chemotherapy.

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

To get a number reading of a CD3+/CD8+ T cell Breast Immunoscore using immunofluorescence (QIF) in posttreatment FFPE tumor biopsy samples collected on day 14-21 of C1 of Pembrolizumab.